|
Detection of haematuria using a reactive test strip
|
46 to 74% for one test, If test repeated over several days: 90 to 95%
|
51 to 84%
|
[190, 198–202]
|
|
Urinary cytology
|
▪ For all tumour grades and stages: 44% [CI 95%, 38–51] [203]
|
▪ For all tumour grades and stages: 96% [CI 95%, 94–98][203]
|
[191–197, 203, 204]
|
|
▪ For Carcinoma in situ (Cis) 70 to 90%
|
▪ For Cis: 90%
|
|
NMP22BC test
|
▪ For all tumour grades and stages: 65% [CI 95%, 50–80] [203]
|
▪ For all tumour grades and stages: 81% [CI 95%, 50–85] [203]
|
[197, 203–209]
|
|
- NMIBC: 81.8%
|
|
- MIBC: 57.1%
|
|
- Grade G1: 83.9%
|
|
- Grade G3: 62.5%
|
|
Fluorescence immunocytochemistry (ImmunoCyt™/uCyt + ™)
|
▪ For all tumour grades and stages: 84% [CI 95%, 77–91] [203]
|
▪ For all tumour grades and stages: 75% [CI 95%, 68–83] [203]
|
[189, 203, 210–213]
|
|
FISH (Fluorescence In Situ Hybridisation) UroVysion™
Kit
|
▪ For all tumour grades and stages: 76% [CI 95%, 65–84] [203]
|
▪ For all tumour grades and stages: 75% [CI 95%, 78–92] [203]
|
[189, 191, 192, 203, 214–218]
|
|
▪ For Cis and G3: >95%
|
